Inozyme Pharma (NASDAQ:INZY) Earns Hold Rating from Jefferies Financial Group

Inozyme Pharma (NASDAQ:INZY)‘s stock had its “hold” rating reissued by analysts at Jefferies Financial Group in a research note issued on Friday,Benzinga reports. They currently have a $4.00 target price on the stock, down from their previous target price of $15.00. Jefferies Financial Group’s price target suggests a potential upside of 1.27% from the company’s previous close.

Several other equities research analysts have also recently weighed in on the company. Needham & Company LLC decreased their price target on Inozyme Pharma from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday. Wedbush reissued an “outperform” rating and issued a $7.00 price target (down previously from $12.00) on shares of Inozyme Pharma in a research note on Monday, March 10th. Raymond James decreased their price target on Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating for the company in a research note on Wednesday, March 12th. Piper Sandler decreased their price target on Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating for the company in a research note on Tuesday, March 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Inozyme Pharma in a research note on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.75.

Inozyme Pharma Price Performance

Inozyme Pharma stock opened at $3.95 on Friday. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $255.02 million, a PE ratio of -2.53 and a beta of 1.35. Inozyme Pharma has a 12 month low of $0.72 and a 12 month high of $6.24. The stock has a 50-day moving average price of $1.09 and a two-hundred day moving average price of $1.87.

Inozyme Pharma (NASDAQ:INZY) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.01). Analysts expect that Inozyme Pharma will post -1.59 EPS for the current year.

Institutional Investors Weigh In On Inozyme Pharma

Large investors have recently added to or reduced their stakes in the business. Harvest Investment Services LLC acquired a new stake in Inozyme Pharma in the fourth quarter valued at approximately $31,000. Graham Capital Management L.P. bought a new stake in Inozyme Pharma during the fourth quarter worth $33,000. China Universal Asset Management Co. Ltd. bought a new stake in Inozyme Pharma during the fourth quarter worth $38,000. 49 Wealth Management LLC bought a new stake in Inozyme Pharma during the first quarter worth $38,000. Finally, D. E. Shaw & Co. Inc. bought a new stake in Inozyme Pharma during the fourth quarter worth $49,000. Institutional investors and hedge funds own 88.30% of the company’s stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.